View Clinical Trial (Medical Research Study)
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
| City: |
|
Baltimore |
| State: |
|
Maryland |
| Zip Code: |
|
21287 |
| Conditions: |
|
Familial Adenomatous Polyposis |
| Purpose: |
|
This clinical trial studies curcumin in treating patients with familial adenomatous
polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal
polyps or colorectal neoplasia
|
| Study Summary: |
|
PRIMARY OBJECTIVES:
I. To determine in a randomized, double-blinded, placebo-controlled study the tolerability
and effectiveness of curcumin to regress intestinal adenomas by measuring duodenal and
colorectal/ileal polyp number, and polyp size in familial adenomatous polyposis patients
with intact colons, ileorectal anastomosis surgery, or ileo-anal pullthrough (reservoir)
surgery.
II. To measure markers of cell proliferation including colorectal mucosal levels of
ornithine decarboxylase (ODC), polyamines, mucosal DNA methylation, proliferative index
(Ki67 antiproliferative cell nuclear antibody), apoptosis index, vascular density, mucosal
prostaglandin, leukotriene levels, and activation of the nuclear factor kappa B (NFKB), and
Akt survival pathways.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive curcumin orally (PO) twice daily (BID) for 12 months.
ARM II: Patients receive placebo PO BID for 12 months.
After completion of study treatment, patients are followed up at 4 months.
|
| Criteria: |
|
Inclusion Criteria:
- Patients with familial adenomatous polyposis who have undergone subtotal colectomy
with ileorectal anastomosis, total coloctomy with ileo-anal pull through (reservoir),
and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or
reservoir
- Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis
without current lower tract adenomatous polyposis i.e. s/p ileostomy
Exclusion Criteria:
- Female patients of childbearing age not on effective birth control
- Pregnant women
- WBC < 3500/ml
- Platelet count < 100,000/ml
- BUN > 25mg%
- Creatinine > 1.5mg%
- Patients unable to stop NSAIDS, aspirin, curcumin, tumeric, calcium, vitamin D, green
tea, or polyphenol E supplements for the duration of the trial
- Malignancy other than nonmelanoma skin cancer
- Active bacterial infection
- Patients with symptoms of active GERD (symptomatic despite medication or current
erosive esophagitis on endoscopy)
- Patients with a history of peptic ulcer disease
- Patients on Warfarin or Plavix
|
| NCT ID: |
|
NCT00641147 |
| Primary Contact: |
|
Principal Investigator Francis Giardiello Johns Hopkins University
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Baltimore, Maryland 21287 United States
Francis M. Giardiello Phone: 410-955-2635 Email: fgiardi@jhmi.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|